Xingjuan Chao Sells 39,000 Shares of CeriBell (NASDAQ:CBLL) Stock

CeriBell, Inc. (NASDAQ:CBLL) CEO Xingjuan Chao sold 39,000 shares of the firm’s stock in a transaction dated Monday, June 8th. The stock was sold at an average price of $18.33, for a total transaction of $714,870.00. Following the transaction, the chief executive officer directly owned 816,317 shares in the company, valued at approximately $14,963,090.61. This represents a 4.56% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.

Xingjuan Chao also recently made the following trade(s):

• On Thursday, May 21st, Xingjuan Chao sold 6,030 shares of CeriBell stock. The stock was sold at an average price of $18.00, for a total transaction of $108,540.00.
• On Tuesday, May 5th, Xingjuan Chao sold 39,000 shares of CeriBell stock. The stock was sold at an average price of $20.10, for a total transaction of $783,900.00.
• On Monday, April 6th, Xingjuan Chao sold 39,000 shares of CeriBell stock. The stock was sold at an average price of $18.40, for a total transaction of $717,600.00.

CeriBell Stock Performance

NASDAQ:CBLL traded up $0.05 during mid-day trading on Wednesday, reaching $18.55. 119,291 shares of the company’s stock were exchanged, compared to its average volume of 316,275. The firm has a market capitalization of $703.82 million, a PE ratio of -11.36 and a beta of 0.84. The company has a debt-to-equity ratio of 0.14, a quick ratio of 10.01 and a current ratio of 10.44. CeriBell, Inc. has a one year low of $10.85 and a one year high of $24.33. The business’s fifty day simple moving average is $18.97 and its two-hundred day simple moving average is $19.63.

CeriBell (NASDAQ:CBLL) last announced its quarterly earnings data on Monday, May 11th. The company reported ($0.52) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.13). The firm had revenue of $26.49 million for the quarter, compared to analyst estimates of $26.09 million. CeriBell had a negative return on equity of 38.19% and a negative net margin of 63.51%. Analysts anticipate that CeriBell, Inc. will post -1.69 earnings per share for the current fiscal year.

Institutional Investors Weigh In On CeriBell

A number of hedge funds have recently made changes to their positions in CBLL. JPMorgan Chase & Co. boosted its stake in shares of CeriBell by 6,424.8% in the 2nd quarter. JPMorgan Chase & Co. now owns 380,003 shares of the company’s stock valued at $7,117,000 after purchasing an additional 374,179 shares in the last quarter. Rhumbline Advisers boosted its stake in shares of CeriBell by 109.9% in the 2nd quarter. Rhumbline Advisers now owns 32,806 shares of the company’s stock valued at $614,000 after purchasing an additional 17,177 shares in the last quarter. New York State Common Retirement Fund boosted its stake in shares of CeriBell by 148.6% in the 2nd quarter. New York State Common Retirement Fund now owns 8,700 shares of the company’s stock valued at $163,000 after purchasing an additional 5,200 shares in the last quarter. Quantbot Technologies LP boosted its stake in shares of CeriBell by 70.3% in the 2nd quarter. Quantbot Technologies LP now owns 15,504 shares of the company’s stock valued at $290,000 after purchasing an additional 6,401 shares in the last quarter. Finally, Invesco Ltd. acquired a new stake in shares of CeriBell in the 2nd quarter valued at approximately $197,000.

Analyst Ratings Changes

CBLL has been the topic of a number of analyst reports. Canaccord Genuity Group reduced their price objective on shares of CeriBell from $28.00 to $25.00 and set a “buy” rating on the stock in a research note on Tuesday, May 12th. Weiss Ratings upgraded shares of CeriBell from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, May 27th. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $22.20.

CeriBell Company Profile

CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.